Spyre Therapeutics Inc

SYRE

Add to Watchlist

74.920USD

-0.730-0.96%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Spyre Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

40 / 382

Overall Ranking

141 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Spyre Therapeutics Inc Highlights

StrengthsRisks

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

Undervalued

The company’s latest PE is -29.28, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 88.99M shares, increasing 14.65% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.52M shares of this stock.

Analyst Rating

Based on 17 analysts

Strong Buy

Current Rating

91.533

Target Price

+21.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Spyre Therapeutics Inc is 5.19, ranking 367 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.19

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Spyre Therapeutics Inc is 5.85, ranking 347 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -29.28, which is -109.99% below the recent high of 2.92 and -4.93% above the recent low of -30.73.

Score

Industry at a Glance

Previous score

5.85

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Spyre Therapeutics Inc is 9.20, ranking 11 out of 382 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 70.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

9.18

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Spyre Therapeutics Inc is 8.98, ranking 40 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 80.09 and the support level at 68.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.06

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Spyre Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.37%, representing a quarter-over-quarter increase of 19.72%. The largest institutional shareholder is PRFDX, holding a total of 1.52M shares, representing 1.76% of shares outstanding, with 432.84% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

11.53M

+28.52%

BlackRock Institutional Trust Company, N.A.

4.99M

+39.08%

Perceptive Advisors LLC

3.07M

+149.64%

RTW Investments L.P.

4.17M

+15.18%

Fairmount Funds Management LLC

4.02M

--

VR Adviser, LLC

3.69M

+37.24%

Deutsch (Peter E)

3.55M

+825.37%

Capital International Investors

3.49M

+45.98%

Driehaus Capital Management, LLC

2.88M

+39.90%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Spyre Therapeutics Inc is 4.84, ranking 63 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 3.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Spyre Therapeutics Inc

SYRE

7.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment